HK Stock Market Move | The FSGS sector is gaining momentum again, and ALEBUND-B (09637) surged over 15%. Institutions indicate that it is expected to enter the Hong Kong Stock Connect.

On August 5, ALEBUND-B (09637) surged dramatically, rising over 15% during the session. As of the time of publication, it was up 13.07%, priced at HKD 33.22, with a trading volume of HKD 29.212 million. In news, US-based kidney disease company Travere Therapeutics released its Q2 2026 results, leading to an after-hours increase of approximately 14%. Its core product, FILSPARI, reported net product sales of USD 141.1 million in the US for Q2, a year-on-year increase of 96%. The initial performance of FSGS and continued growth in the IgA nephropathy business contributed to the initiation of 2,012 new patient cases. In April of this year, FILSPARI received FDA approval as the first treatment for FSGS, a long-underserved kidney condition that is being repriced by the capital markets. The excitement around FSGS has prompted the market to reevaluate Libang Pharmaceutical's position in the same indication. The company's self-developed AP303 is a dual PPAR agonist, positioned as a potentially groundbreaking disease-modifying therapy that may delay or prevent the progression of CKD. The company holds global rights covering high proteinuria patients with FSGS, DKD, and IgAN (basket phase II) as well as ADPKD (which has received FDA orphan drug designation). AP303 has completed phase I clinical trials and is expected to progress to phase II in the second half of the year, currently standing at the starting point of clinical value realization. Notably, CICC recently released a research report stating that the Hang Seng Index company will announce its review results on August 21, coinciding with the semi-annual review of the Hang Seng Composite Index. The institution estimates that 49 stocks are expected to be included in the Hong Kong Stock Connect, including Libang Pharmaceutical. It is reported that being included in the Hong Kong Stock Connect will help expand the companys investor base and potentially increase liquidity in H shares.